BioCentury
ARTICLE | Company News

Genmab, TenX Biopharma deal

February 8, 2010 8:00 AM UTC

TenX received exclusive, worldwide rights to develop and commercialize Genmab's zanolimumab ( HuMax-CD4). In 2008, Genmab said it was discontinuing development of zanolimumab due to the "relatively small market potential" in cutaneous T cell lymphoma (CTCL) and "the significant investment required to take the product through to approval." TenX plans to resume a Phase III trial of the human mAb against CD4 to treat CTCL that TenX said Genmab had placed on hold. TenX plans to present data from the trial this year and said it hopes to submit regulatory applications in the U.S. and Europe for zanolimumab in 2011. ...